Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
about
The development and assessment of biological treatments for children.Endobronchial carcinoid tumor in a Crohn disease patient treated with a TNFα inhibitorBiologics in paediatric Crohn's disease.Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseUse of immunomodulators and biologic therapies in children with inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Advances in the medical management of paediatric IBD.Adalimumab in the treatment of immune-mediated diseases.Biologic response modifiers and pediatric psoriasis.Adalimumab for the treatment of pediatric Crohn's disease.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy.Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Association of Autism Spectrum Disorders and Inflammatory Bowel Disease.Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease.Childhood onset of Crohn disease: experience from a university teaching hospital in Saudi Arabia.
P2860
Q35135936-8B34D466-696B-40AF-B89B-9F82FCB1254CQ35200493-7486D1E0-7928-4546-9D00-CBC9C7CE5469Q35579308-301436B6-92F0-4A13-96F1-A4E3EB93C93BQ35692293-A8C3C8D0-C5D8-478F-992C-3A3E212058B6Q37463702-278BE228-4AB7-41F4-8498-FA2B07A37E74Q37609746-E5642C01-9716-4DF3-BF2E-5117F54FFC7FQ37769253-21A92134-2E9E-4077-B474-0431DB1CDEACQ37820898-F7A42CB6-ADB6-4E4C-BAAC-5D0CA05170C7Q37853354-67A8D49F-1C5A-4042-8E6D-596E7222C0B5Q37860252-E4D97CC7-543F-40EA-BF84-D096FC672DC5Q37936394-2CE7F918-B714-4C18-9E06-CA4434C38941Q38130044-82D5B6C3-B7BD-4FC4-A8BA-00889C92641BQ38207760-A933A349-7694-489E-B59B-0F6DDD78C703Q38366432-10F717CD-CD06-4C6D-97B5-BE45FA643C05Q38554433-36FC1C86-0C6C-49C1-A008-CFE6CC857B7EQ38619950-542ABEFD-9EF6-4804-9C3A-62756C25FF5EQ39030608-D16D3C2D-6D91-4B56-810D-436E41EE17D9Q40237363-D9D3D2AA-1CDB-4863-9BF6-038AC17273E5Q46336967-457AF664-1B45-4FAE-8321-29E49FF5C09DQ47805665-266F8C64-DBA9-4351-9AB2-810369B8D11BQ47952858-562A5919-1C10-42BA-9C6C-881194C24E71Q49500732-8A1BC08C-C2B9-4EE7-95BD-5D2CB4925DC2Q50526241-43EAA566-DE4C-4A45-A0A4-5BCC1283FBDDQ50872867-C710D933-CA23-4638-ACF0-0FEEFE216637
P2860
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@en
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@nl
type
label
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@en
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@nl
prefLabel
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@en
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@nl
P2093
P2860
P50
P356
P1476
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
@en
P2093
Franca Viola
Maria Beatrice Barbato
Osvaldo Borrelli
P2860
P2888
P304
P356
10.1038/AJG.2009.372
P407
P577
2009-06-23T00:00:00Z
P5875
P6179
1052306486